文献速递肿瘤 PET/CT神经核医学

BRAF-MEK联合治疗BRAFV600E突变盲肠神经内分泌癌伴难治性乳酸酸中毒的代谢反应

Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.
PubMed 文献 · Clin Nucl Med · 2018-01-01

本文报告一例49岁女性晚期盲肠高级别神经内分泌癌伴体细胞BRAF突变,对标准化疗难治并出现危及生命的高乳酸血症。开始BRAF-MEK治疗(达拉非尼联合曲美替尼)后早期,PET/CT显示盲肠原发灶及淋巴结、肝、骨转移灶的病理性FDG摄取大幅下降,总病灶糖酵解减少与临床反应及乳酸水平正常化严格相关。

要点

  • BRAF-MEK联合治疗早期即可见盲肠原发灶及淋巴结、肝、骨转移灶FDG摄取大幅下降。
  • PET/CT总病灶糖酵解下降与临床反应及乳酸水平正常化严格相关。
  • 本例为BRAFV600E突变盲肠高级别神经内分泌癌伴难治性乳酸酸中毒的个案报告。

核心结论

  • BRAF-MEK联合治疗在BRAFV600E突变盲肠高级别神经内分泌癌伴难治性乳酸酸中毒患者中早期即出现PET/CT代谢反应,总病灶糖酵解下降与临床反应及乳酸水平正常化严格相关。

主要发现

  • 患者对标准化疗难治,表现为危及生命的高乳酸血症。
  • 开始BRAF-MEK治疗(达拉非尼联合曲美替尼)后早期,PET/CT显示盲肠原发肿瘤及淋巴结、肝、骨转移灶的病理性FDG摄取大幅下降。
  • PET/CT图像上总病灶糖酵解的减少与患者显著的临床反应及乳酸水平正常化严格相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report the results of serial F-FDG PET/CT investigations in a 49-year-old woman presenting with an advanced cecal high-grade neuroendocrine carcinoma harboring a somatic BRAF mutation. Patient was refractory to standard chemotherapy regimen showing life-threatening hyperlactatemia. Early after the beginning of BRAF-MEK therapy (dabrafenib and trametinib), impressive improvement in PET/CT imaging was achieved. The pathological F-FDG uptake in cecal primary tumor as well as in nodal, hepatic, and bone metastases drastically decreased. Moreover, the reduction of total lesion glycolysis on PET/CT images was strictly related to extraordinary patient clinical response and lactic acid level normalization.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Imperiale A, Latgé A, Schaff-Wendling F, et al. Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis. Clin Nucl Med. 2018. PMID: 30036245. doi:10.1097/RLU.0000000000002231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。